DOCSLIB.ORG

Quinolones a Systematic Quest

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quinolones a Systematic Quest Quinolones A Systematic Quest David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts© by General author Hospital Harvard Medical School ESCMID Online Lecture Library Timeline of Quinolone Development © by author ESCMIDNorris S, Mandell Online GL in Andriole Lecture V (ed). The Library Quinolones 1988 © by author George Y. Lesher, Ph.D. ESCMID Online1926- Lecture1990 Library Surprise Beginnings O COOH N N H3C C2H5 © by author Nalidixic Acid ESCMID Online Lecture Library Quinolones The First Decade (Childhood) • 1962 Discovery of Nalidixic Acid as anti- bacterial byproduct of chloroquine synthesis (Lesher) • 1964-66 Mechanisms of Action Defined (Goss, Dietz, Cook) » Inhibition of DNA synthesis » Conditional bactericidal activity • 1967 Nalidixic Acid released for clinical use for treatment of© urinary by author tract infections caused by enteric bacteria • 1969 Resistance to Nalidixic Acid in E. coli ESCMID mapped Online to chromosomal Lecture mutations Library (nalA,B) (Hane) Quinolones The Second Decade (Adolescence) • 1970 Development of Piromidic Acid, the 1st pyrrolindinyl quinolone • 1975 Development of Pipemidic Acid, the 1st piperazinyl quinolone • 1976 Discovery of DNA gyrase, the 1st type 2 topoisomerase (Gellert) • 1976 Development of Flumequine, the 1st fluoroquinolone© andby tricyclicauthor quinolone • 1977 Nalidixic Acid resistance loci identified as encoding mutant subunits of DNA gyrase ESCMIDof E. coli Online (Gellert, LectureCozzarelli) Library Piromidic Acid Pipemidic Acid © by author ESCMID OnlineFlumequine Lecture Library Quinolones - The Third Decade (Adolescent Growth Spurt) • 1986 Norfloxacin released for clinical use in US (GU infections) • 1986 Development of Fleroxacin, 1st 6, 8- difluoroquinolone (recognition of photosensitivity associated with 8-F) • 1987 Ciprofloxacin released for clinical use in US (broad ©indications) by author • 1988-89 Identification of drug resistance by altered permeation for hydrophilic quinolones - active ESCMID efflux andOnline altered Lecture porins Library O O F COOH F COOH HN N N HN N N C H Norfloxacin 2 5 O F COOH Ciprofloxacin H3C N N N © by author F CH2 CH2 ESCMIDFleroxacin OnlineF Lecture Library Quinolone Phototoxicity • UVA (320-420 nm) interactions • Generation of reactive oxygen species • Drug concentrations in skin • SARs – Position 8: C-halogen > N-H > C-H > C-O-R – Position 7: Alkylated© by authorrings increase t½ – Position 5: CH3 > H > NH2 ESCMID Online Lecture Library Quinolones - The Fourth Decade (Problems of Adolescence) • 1990 Ofloxacin PO/IV released for clinical use in US (broad indications) • 1990 Discovery of Topoisomerase IV (Kato) • 1991 Enoxacin PO released in US (GU indications) • 1992 Temafloxacin released and withdrawn due to unexpected rare but severe toxicities (Hemolytic©-Uremic by author Syndrome) • 1992 Lomefloxacin PO released in US, 1st once- daily fluoroquinolone • 1993ESCMID-94 Identification Online of Lecture quinolone Libraryinhibition of topoisomerase IV of E. coli O O F COOH F COOH HN N N N HN N N C2H5 Enoxacin F C2H5 H3C O Lomefloxacin F COOH O F COOH HCl N N F © by author HN H3C N N N O * CH3 CH3 ESCMID Online LectureOfloxacin Library Temafloxacin F Quinolones - The Fourth Decade (Adulthood) • 1994-96 Identification of topoisomerase IV as principal quinolone target in S. aureus and secondary target in E. coli • 1996 Levofloxacin PO/IV and sparfloxacin PO released in US (expanded Gram+ respiratory indications) • 1997 Grepafloxacin© by PO author (Respiratory/GU Indications) and Trovafloxacin PO/IV (broadest indications, 1st anti-anaerobic ESCMID quinolone) Online released Lecture in US Library O NH2 O F COOH F COOH H3C H3C N N N HN N N O F CH3 H3C Sparfloxacin Levofloxacin O F CO2H CH3 O F CO H 2 N H N N F CH3 © by author N N H2N HN H GrepafloxacinESCMID Online LectureTrovafloxacin Library F Quinolones - The Fourth Decade (Adults Have Their Ups & Downs) • 1998 Plasmid transferable quinolone resistance identified • 1999 Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temafloxacin) • 1999 Grepafloxacin withdrawn because of cardiac events. Sparfloxacin© by author also associated with arrhythmias • 1999 Gatifloxacin PO/IV and Moxifloxacin PO ESCMID released Online with a focus Lecture on respiratory Library tract indications Rare, Serious Idiosyncratic Reactions • Temafloxacin (1992) – Hemolytic uremic syndrome – Coagulopathy (35%) – Hepatic dysfunction (51%) – Reporting incidence ~1:6000 • Trovafloxacin (1999) – Symptomatic hepatitis© by author – Life-threatening in ~10% – Reporting incidence ~1:18,000 ESCMID OnlineBlum MD Lectureet al. 1994. ClinLibrary Infect Dis 18:946 Ball P et al. 1999. Drug Safety 21:407 Quinolones - The Fourth Decade (Adults Have Their Ups & Downs) • 1999 Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temfloxacin) • 1999 Grepafloxacin withdrawn because of cardiac events. Sparfloxacin also associated with arrhythmias © by author • 1999 Gatifloxacin PO/IV and Moxifloxacin PO released with a focus on respiratory tract ESCMID indications Online Lecture Library Effects of Drugs on Cardiac Conduction a b Drug QTC Prolongation Ikr hERG IC30 (msec) (µM) (µM) Sparfloxacin 13-15 0.23 10 Grepafloxacin 10 27.2 39 Moxifloxacin 7 -- 92 Gatifloxacin 5-6 26.5 104 Terfenidine 46 © by author Erythromycin 8-15 aAnderson et al. 3rd ECC ClarithromycinESCMID Online2-6 bChen Lecture et al. ICAAC Library 2000 abstr 765 Quinolones - The Fourth Decade (Adults Have Their Ups & Downs) • 1999 Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temfloxacin) • 1999 Grepafloxacin withdrawn because of cardiac events. Sparfloxacin also associated with arrhythmias © by author • 1999 Gatifloxacin PO/IV and Moxifloxacin PO released with a focus on respiratory tract ESCMID indications Online Lecture Library Quinolone Structure-Activity Relationships © by author ESCMID Online Lecture Library Domagala JM. 1994. J Antimicrob Chemother 33:685 Quinolone Structure-Adverse Effects Relationships © by author ESCMIDDomagala JM. Online 1994. J Antimicrob Lecture Chemother Library 33:685 Quinolones - The Fifth Decade (Adults Have Their Ups & Downs) • 2002 Plasmid-encoded Qnr protein identified as protecting gyrase from quinolones • 2003 Gemifloxacin approved for community- acquired pneumonia with 5-day regimen • 2006 Plasmid-encoded quinolone-modifying enzyme identified as mutant AAC(6’)-Ib • 2007 Plasmid-encoded© by QepAauthor efflux pump identified • 2008 Gatifloxacin withdrawn because of ESCMID dysglycemia Online events Lecture Library • 2009 First topoisomerase IV-DNA crystal structures with quinolone bound © by author Laponogov I et al. Nature Struct Mol Biol. ESCMID Online Lecture2009; 16:667Library The Fluoroquinolone Family American Branch – The Sixth Decade 12 Approvals over 17 Years • Norfloxacin (Noroxin) • SparfloxacinXXX (Zagam) 1986 1996 • Ciprofloxacin (Cipro) • GrepafloxacinXXX (Raxar) 1987 PO, 1990 IV 1997 • Ofloxacin (Floxin) • TrovafloxacinXXX (Trovan) 1990 PO, 1992 IV 1997 • EnoxacinXXX (Penetrex) • GatifloxacinXXX (Tequin) 1991 © by author1999 • LomefloxacinXXX (Maxaquin) • Moxifloxacin (Avelox) 1992 1999 • LevofloxacinESCMID (Levaquin) Online Lecture• Gemifloxacin Library (Factive) 1996 2003 Adverse Effects of Fluoroquinolones • Gastrointestinal – Nausea, vomiting, diarrhea • Central Nervous System – Dizziness (trovafloxacin), insomnia, seizures • Cardiovascular – QTC prolongation (sparfloxacin, grepafloxacin > moxifloxacin) • Hepatic – Idiosyncratic hepatitis (trovafloxacin) • Metabolic – Dysglycemia (gatifloxacin > levofloxacin) • Skin © by author – Photosensitivity (sparfloxacin, lomefloxacin) – Other skin reactions (gemifloxacin) • Musculoskeletal – ESCMIDTendinopathy Online Lecture Library Quinolones – The Sixth Decade Senescence or New Generations to Follow The Search Goes On • Keys to success: – Dealing with established resistance – Low potential for new resistance © by author – High tolerability (no surprises – better preclinical screening tools) ESCMID Online Lecture Library Problems With Development of Bacterial Resistance to Fluoroquinolones Staphylococci (MRSA, MRSE) 60-95% Pseudomonas aeruginosa 5-30% Campylobacter jejuni 3-50% Escherichia coli 8-26% Neisseria gonorrheae© by author 6-70% Streptococcus pneumoniae 3% ESCMID Online Lecture Library Predicting Resistance Potential: (Which Quinolone Will Live the Longest?) • Determinants of bacterial resistance – Activity against both target enzymes, DNA gyrase and DNA topoisomerase IV – Effects of native bacterial efflux systems – Potency that keeps© by drug author concentrations above the MIC of first-step resistant mutants (mutant prevention ESCMIDconcentration) Online Lecture Library Sitafloxacin O F CO2H N N Cl F H2N Activity: S. pneumoniae (16x) Other streptococci (16-32x) (Relative to Enterococci (16x) Ciprofloxacin) S. aureus (>2-32x) B. fragilis (64x) P. aeruginosa (1-6x) © by author→ µ Pharmacokinetics: 500mg PO Cmax 4.6 g/ml t 1/2 = 4.5-5h; renal (70%) Vd = 1.8 liters ESCMID OnlineAnderson Lecture DL. Drugs Library of Today 2008; 44:489. Prulifloxacin/Ulifloxacin Activity: S. pneumoniae (1x) S. pyogenes (1x) (Relative to Enterococci (1x) Levofloxacin) S. aureus (1x) Klebsiella spp. (4x) © byEnterobacter author spp. (4x) P. aeruginosa (0.5-2x) ESCMIDMontanari MP Online et al. Antimicrob Lecture Agents Chemother. Library 2001; 45:3616 Finafloxacin Organism MIC (median, μg/ml) pH 5.0 pH 7.3 Fin Cip Fin Cip E. coli CipS 0.031 0.5 0.125 0.016
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Crystal Structure and Stability of Gyrase–Fluoroquinolone Cleaved Complexes from Mycobacterium Tuberculosis
    Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis Tim R. Blowera,1, Benjamin H. Williamsonb, Robert J. Kernsb, and James M. Bergera,2 aDepartment of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and bDivision of Medicinal and Natural Products Chemistry, University of Iowa, Iowa City, IA 52242 This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2013. Contributed by James M. Berger, December 22, 2015 (sent for review October 28, 2015; reviewed by Benjamin Bax and Yuk-Ching Tse-Dinh) Mycobacterium tuberculosis (Mtb) infects one-third of the world’s threatens both first-line and second-line use (11). The wide- population and in 2013 accounted for 1.5 million deaths. Fluoro- spread testing of fluoroquinolones against TB has revealed quinolone antibacterials, which target DNA gyrase, are critical considerable variation in efficacy of different drug variants agents used to halt the progression from multidrug-resistant tu- against Mtb. For example, ciprofloxacin is only marginally active, berculosis to extensively resistant disease; however, fluoroquino- and its early use with Mtb was halted in favor of ofloxacin and lone resistance is emerging and new ways to bypass resistance are levofloxacin (7). These two agents are now proving to be less required. To better explain known differences in fluoroquinolone effective than moxifloxacin and gatifloxacin (7, 10); however, the action, the crystal structures of the WT Mtb DNA gyrase cleavage newest two compounds also exhibit some nonideality. For ex- core and a fluoroquinolone-sensitized mutant were determined in ample, gatifloxacin can elicit side effects such as hypo/hypergly- complex with DNA and five fluoroquinolones.
    [Show full text]
  • Clinically Isolated Chlamydia Trachomatis Strains
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h.
    [Show full text]
  • Second and Third Generation Oral Fluoroquinolones
    Therapeutic Class Overview Second and Third Generation Oral Fluoroquinolones Therapeutic Class • Overview/Summary: The second and third generation quinolones are approved to treat a variety of infections, including dermatologic, gastrointestinal, genitourinary, respiratory, as well as several miscellaneous infections.1-10 They are broad-spectrum agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.11,12 The quinolones are most active against gram-negative bacilli and gram-negative cocci.12 Ciprofloxacin has the most potent activity against gram-negative bacteria. Norfloxacin, ciprofloxacin and ofloxacin have limited activity against streptococci and many anaerobes while levofloxacin and moxifloxacin have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.11-12 Gemifloxacin, levofloxacin and moxifloxacin are considered respiratory fluoroquinolones. They possess enhanced activity against Streptococcus pneumoniae while maintaining efficacy against Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens. Resistance to the quinolones is increasing and cross-resistance among the various agents has been documented. Two mechanisms of bacterial resistance have been identified. These include mutations in chromosomal genes (DNA gyrase and/or topoisomerase IV) and altered drug permeability across the bacterial cell membranes.11-12 Clinical Guidelines support
    [Show full text]
  • Treatment of Bacterial Urinary Tract Infections: Presence and Future
    european urology 49 (2006) 235–244 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review - Infections Treatment of Bacterial Urinary Tract Infections: Presence and Future Florian M.E. Wagenlehner *, Kurt G. Naber Urologic Clinic, Hospital St. Elisabeth, Straubing, Germany Article info Abstract Article history: Bacterial urinary tract infections (UTIs) are frequent infections in the Accepted December 12, 2005 outpatient as well as in the nosocomial setting. The stratification into Published online ahead of uncomplicated and complicated UTIs has proven to be clinically useful. print on January 4, 2006 Bacterial virulence factors on the one side and the integrity of the host defense mechanisms on the other side determine the course of the Keywords: infection. In uncomplicated UTIs Escherichia coli is the leading organism, Urinary tract infections (UTI) whereas in complicated UTIs the bacterial spectrum is much broader Uncomplicated and including Gram-negative and Gram-positive and often multiresistant complicated UTI organisms. The therapy of uncomplicated UTIs is almost exclusively Antibiotic resistance of antibacterial, whereas in complicated UTIs the complicating factors uropathogens have to be treated as well. There are two predominant aims in the Antibiotic treatment antimicrobial treatment of both uncomplicated and complicated UTIs: New antiinfectives for (i) rapid and effective response to therapy and prevention of recurrence treatment of UTI of the individual patient treated; (ii) prevention of emergence of resis- tance to antimicrobial chemotherapy in the microbial environment. The main drawback of current antibiotic therapies is the emergence and rapid increase of antibiotic resistance. To combat this development several strategies can be followed. Decrease the amount of antibiotics administered, optimal dosing, prevention of infection and development of new antibiotic substances.
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Fluoroquinolones in Children: a Review of Current Literature and Directions for Future Research
    Academic Year 2015 - 2016 Fluoroquinolones in children: a review of current literature and directions for future research Laurens GOEMÉ Promotor: Prof. Dr. Johan Vande Walle Co-promotor: Dr. Kevin Meesters, Dr. Pauline De Bruyne Dissertation presented in the 2nd Master year in the programme of Master of Medicine in Medicine 1 Deze pagina is niet beschikbaar omdat ze persoonsgegevens bevat. Universiteitsbibliotheek Gent, 2021. This page is not available because it contains personal information. Ghent Universit , Librar , 2021. Table of contents Title page Permission for loan Introduction Page 4-6 Methodology Page 6-7 Results Page 7-20 1. Evaluation of found articles Page 7-12 2. Fluoroquinolone characteristics in children Page 12-20 Discussion Page 20-23 Conclusion Page 23-24 Future perspectives Page 24-25 References Page 26-27 3 1. Introduction Fluoroquinolones (FQ) are a class of antibiotics, derived from modification of quinolones, that are highly active against both Gram-positive and Gram-negative bacteria. In 1964,naladixic acid was approved by the US Food and Drug Administration (FDA) as first quinolone (1). Chemical modifications of naladixic acid resulted in the first generation of FQ. The antimicrobial spectrum of FQ is broader when compared to quinolones and the tissue penetration of FQ is significantly deeper (1). The main FQ agents are summed up in table 1. FQ owe its antimicrobial effect to inhibition of the enzymes bacterial gyrase and topoisomerase IV which have essential and distinct roles in DNA replication. The antimicrobial spectrum of FQ include Enterobacteriacae, Haemophilus spp., Moraxella catarrhalis, Neiserria spp. and Pseudomonas aeruginosa (1). And FQ usually have a weak activity against methicillin-resistant Staphylococcus aureus (MRSA).
    [Show full text]
  • Dead Bugs Don't Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
    PERSPECTIVES Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance Charles W. Stratton*1 The global emergence of antibacterial resistance among and macrolides (the antibacterial agents used most frequently common and atypical respiratory pathogens in the last decade for pneumococcal infections) have become prevalent through- necessitates the strategic application of antibacterial agents. out the world. Indeed, rates of S. pneumoniae resistance to The use of bactericidal rather than bacteriostatic agents as penicillin now exceed 40% in many regions, and a high pro- first-line therapy is recommended because the eradication of portion of these strains are also resistant to macrolides. More- microorganisms serves to curtail, although not avoid, the devel- over, the trend is growing rapidly. Whereas 10.4% of all S. opment of bacterial resistance. Bactericidal activity is achieved with specific classes of antimicrobial agents as well as by com- pneumoniae isolates were resistant to penicillin and 16.5% bination therapy. Newer classes of antibacterial agents, such resistant to macrolides in 1996, these proportions rose to as the fluoroquinolones and certain members of the macrolide/ 14.1% and 21.9%, respectively, in 1997 (9). A more recent lincosamine/streptogramin class have increased bactericidal susceptibility study conducted in 2000–2001 showed that activity compared with traditional agents. More recently, the 51.5% of all S. pneumoniae isolates were resistant to penicillin ketolides (novel, semisynthetic, erythromycin-A derivatives) and 30.0% to macrolides (10). have demonstrated potent bactericidal activity against key res- The urgent need to curtail proliferation of antibacterial- piratory pathogens, including Streptococcus pneumoniae, Hae- resistant bacteria has refocused attention on the proper use of mophilus influenzae, Chlamydia pneumoniae, and Moraxella antibacterial agents.
    [Show full text]
  • Eye Infections
    CLINICAL Approach Taking a Look at Common Eye Infections John T. Huang, MD, FRCSC and Peter T. Huang, MD, FRCSC he acutely red eye is often seen first by the primary-care physician. The exact Tcause may be difficult to determine and may cause some concern that a serious ocular condition has been missed. Thorough history and clinical examination will help delineate the final diagnosis. When there are doubts, prompt referral to an oph- thalmologist can prevent serious consequences. Often, the most likely diagnosis of an acutely red eye is acute conjunctivitis. In the first day, an acute bacterial infection may be hard to differentiate from viral, chlamydial and noninfectious conjunctivitis and from episcleritis or scleritis. Below is a review of the most commonly seen forms of eye infections and treat- ments. Failure to improve after three to five days should lead to a re-evaluation of the patient and appropriate referral where necessary. CHRONIC BLEPHARITIS Clinical: Gritty burning sensation, mattering, lid margin swelling and/or scaly, flaky debris, mild hyperemia of conjunctiva; may have acne rosacea or hyperkeratotic dermatitis (Figure 1). Anterior: Staphylococcus aureus (follicles, accessory glands); posterior (meibomian glands). Treatment: • Lid scrubs (baby shampoo, lid-care towellettes, warm compresses). Figure 1. Chronic blepharitis. There may be localized sensitivity to the shampoo or the components of the solution in the towellettes (e.g., benzyl alcohol). • Hygiene is important for the treatment and management of chronic blepharitis. Topical antibiotic-corticosteroid combinations (e.g., tobramycin drops, tobramycin/dexamethasone or sulfacetamide sodium-prednisolone acetate). Usage of these medications is effective in providing symptomatic relief, as the inflammatory component of the problem is more effectively dealt with.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Fluoroquinolones in the Management of Acute Lower Respiratory Infection
    Thorax 2000;55:83–85 83 Occasional review Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults Peter J Moss, Roger G Finch Lower respiratory tract infections (LRTI) are ing for up to 40% of isolates in Spain19 and 33% the leading infectious cause of death in most in the United States.20 In England and Wales developed countries; community acquired the prevalence is lower; in the first quarter of pneumonia (CAP) and acute exacerbations of 1999 6.5% of blood/cerebrospinal fluid isolates chronic bronchitis (AECB) are responsible for were reported to the Public Health Laboratory the bulk of the adult morbidity. Until recently Service as showing intermediate sensitivity or quinolone antibiotics were not recommended resistance (D Livermore, personal communi- for the routine treatment of these infections.1–3 cation). Pneumococcal resistance to penicillin Neither ciprofloxacin nor ofloxacin have ad- is not specifically linked to quinolone resist- equate activity against Streptococcus pneumoniae ance and, in general, penicillin resistant in vitro, and life threatening invasive pneumo- pneumococci are sensitive to the newer coccal disease has been reported in patients fluoroquinolones.11 21 treated for respiratory tract infections with Resistance to ciprofloxacin develops rela- these drugs.4–6 The development of new fluoro- tively easily in both S pneumoniae and H influ- quinolone agents with increased activity enzae, requiring only a single mutation in the against Gram positive organisms, combined parC gene.22 23 Other quinolones such as with concerns about increasing microbial sparfloxacin and clinafloxacin require two resistance to â-lactam agents, has prompted a mutations in the parC and gyrA genes.11 23 re-evaluation of the use of quinolones in LRTI.
    [Show full text]